Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283334 · ClinicalTrials.gov registry record · Phase 1
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01283334 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT01283334, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test the drug RAD001 in combination with other chemotherapy drugs, Carboplatin and Cetuximab. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination. The investigators will test the safety of RAD001 in combination with Carboplatin and Cetuximab and see what effects (good and/or bad) it has on your cancer, and find the highest dose of RAD001 that can be given without causing bad side effects. The doses of Carboplatin and Cetuximab will not be varied as both these drugs are considered to be part of the current standard of care for patients with your condition.
Interventions
- DRUG Carboplatin
- DRUG Cetuximab
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283334
The ClinicalTrials.gov registry entry for NCT01283334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01283334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283334 about?
NCT01283334 is a clinical study titled "A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer". The purpose of this study is to test the drug RAD001 in combination with other chemotherapy drugs, Carboplatin and Cetuximab. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination. The investigators will test the safety of RAD0...
What is the current status of trial NCT01283334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-01. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01283334?
The interventions under investigation include: Carboplatin (DRUG), Cetuximab (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT01283334?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.